Get the Stockscreener App
35.01
0.26%
-0.09
Roivant Sciences Ltd stock is traded at $35.01, with a volume of 4.04M.
It is down -0.26% in the last 24 hours and up +2.94% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$35.10
Open:
$35.23
24h Volume:
4.04M
Relative Volume:
0.69
Market Cap:
$25.18B
Revenue:
$8.26M
Net Income/Loss:
$-397.91M
P/E Ratio:
-69.52
EPS:
-0.5036
Net Cash Flow:
$-758.56M
1W Performance:
+1.45%
1M Performance:
+2.94%
6M Performance:
+55.05%
1Y Performance:
+207.64%
1-Day Range:
$34.80
$35.59
1-Week Range:
$33.96
$35.70
52-Week Range:
$10.90
$37.00
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
35.01 | 25.18B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Outperform |
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Dimensional Fund Advisors LP Sells 1,771,602 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bank of Nova Scotia Cuts Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Allspring Global Investments Holdings LLC Buys New Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV) Edges Lower as Stock Consolidates Near Support ZoneInsider Sentiment - dars.gov.et
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
California Public Employees Retirement System Invests $19.15 Million in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance UK
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 - marketscreener.com
Roivant to Host Immunovant’s Aug. 6 Business Update Webcast - Stock Titan
Baader Bank Aktiengesellschaft Sells 33,612 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Bank of New York Mellon Corp Decreases Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Form 4 Roivant Sciences Ltd. For: 21 July By Investing.com - Investing.com Nigeria
Form 4 Roivant Sciences Ltd. For: 21 July - Investing.com India
Roivant Sciences (ROIV) grants director Oren Ilan 775 fully vested shares - Stock Titan
Responsive Playbooks and the ROIV Inflection - Stock Traders Daily
Illinois Municipal Retirement Fund Boosts Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a 13.93% Upside in Biotech Innovation - DirectorsTalk Interviews
Why is Billionaire Joe Edelman Bullish on Roivant Sciences (ROIV) - Kavout | AI
Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine tech - Seeking Alpha
Roivant unit Genevant, Arbutus file patent infringement suits against Pfizer, BioNTech over LNP technology - Bitget
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring the 9.47% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Roivant Sciences (ROIV) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Roivant’s Gline: From spin-cos to commercial conviction - BioCentury
Roivant Sciences (ROIV) Climbs 2%: Biotech Stock Tests Key Resistance Near $38.65Moving Average Ribbon - dars.gov.et
Roivant Sciences (ROIV) TD Cowen 45th Annual Healthcare Conference Summary - Quartr
Roivant Sciences stock hits all-time high at 35.92 USD By Investing.com - Investing.com Nigeria
Roivant Sciences stock hits all-time high at 35.92 USD - Investing.com
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? - Yahoo Finance
Roivant Sciences Ltd. (ROIV) Stock Analysis: Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
If You Invested $1,000 in Roivant Sciences (ROIV) - Stock Titan
ROIVRoivant Sciences Ltd Dividends - Finviz
Roivant Sciences Insider Sold Shares Worth $610,252, According to a Recent SEC Filing - Moomoo
Roivant Sciences (ROIV) director exercises options, sells 10,000 common shares - Stock Titan
Roivant Sciences (ROIV) Edges Lower, Consolidating Between Key Support and Resistance LevelsRegression Channel - dars.gov.et
Roivant Sciences (ROIV) Left Key Russell Indexes, Is It Still 10% Below Fair Value? - simplywall.st
Tax withholding trims Frank Torti’s Roivant Sciences (ROIV) share count - Stock Titan
Roivant Sciences (ROIV) director sells 17,750 shares after exercising options - Stock Titan
Roivant Sciences Insider Sold Shares Worth $56,444,076, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences Insider Sold Shares Worth $49,354,076, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences (ROIV) director-linked entity reports 1.44M-share open-market sale - Stock Titan
Form 144 ROIVANT SCIENCES LTD. For: 30 June - Investing.com UK
Roivant Sciences(ROIV.US) Director Sells US$56.44 Million in Common Stock - Moomoo
Roivant Sciences Director Sold Shares Worth Over $56M - TradingView
Form 144 ROIVANT SCIENCES LTD. For: 30 June By Investing.com - Investing.com Nigeria
Is Roivant Sciences (ROIV) Losing Its Defensive Status or Reframing Its Risk Narrative? - simplywall.st
Roivant Sciences Insider Sold Shares Worth $34,105,000, According to a Recent SEC Filing - Moomoo
Roivant Sciences Ltd.(NasdaqGS: ROIV) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Roivant Sciences Ltd.(NasdaqGS: ROIV) dropped from Russell 1000 Defensive Index - marketscreener.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: A Biotech Powerhouse with 14.59% Potential Upside - DirectorsTalk Interviews
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Roivant Sciences Ltd Stock (ROIV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fitzgerald Meghan | Director |
Jun 30 '26 |
Sale |
34.90 |
10,000 |
349,000 |
42,963 |
| Epperly Melissa B, | Director |
Jun 29 '26 |
Option Exercise |
4.46 |
17,750 |
79,165 |
34,224 |
| Epperly Melissa B, | Director |
Jun 29 '26 |
Sale |
34.38 |
17,750 |
610,252 |
16,474 |
| MANCHESTER KEITH S | Director |
Jun 29 '26 |
Sale |
34.55 |
800,000 |
27,642,000 |
13,701,546 |
| MANCHESTER KEITH S | Director |
Jun 26 '26 |
Sale |
34.00 |
625,783 |
21,275,309 |
14,501,546 |
| MANCHESTER KEITH S | Director |
Jun 30 '26 |
Sale |
35.45 |
200,000 |
7,090,000 |
1,748,403 |
| MANCHESTER KEITH S | Director |
Jun 30 '26 |
Sale |
35.28 |
12,380 |
436,766 |
13,689,166 |
| Gold Daniel Allen | Director |
Jun 29 '26 |
Sale |
34.55 |
800,000 |
27,642,000 |
13,701,546 |
| Gold Daniel Allen | Director |
Jun 26 '26 |
Sale |
34.00 |
625,783 |
21,275,309 |
14,501,546 |
| Gold Daniel Allen | Director |
Jun 30 '26 |
Sale |
35.28 |
12,380 |
436,766 |
13,689,166 |
0.32%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):